Update: PharmaJet Needle-free COVID-19 Vaccine Trial
GOLDEN, Colo. — June 30, 2020 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that patient enrollment has started for the phase 1 trial in Australia using its Needle-free Injection Systems to deliver a vaccine against SARS-CoV-2. COVIGEN, a DNA-based vaccine was developed by French-Thai pharmaceutical company BioNet-Asia in collaboration with and Melbourne-based biotech Technovalia. The PharmaJet System was chosen due to its record of increasing the effectiveness of DNA vaccines, ease-of-use, and speed of the delivery system compared to traditional needle and syringe. DetailsPharmaJet Announces Addition of Paul LaBarre as VP Global Business Development
GOLDEN, Colo. — June 15, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that Paul LaBarre, has joined the leadership team as Vice President, Global Business Development. Mr. LaBarre is a global business executive with over 20 years of global health experience across the innovation value chain including strategy, research, product development, and strategic business development, most notably with UNICEF and PATH. In this role he will be leading business development and commercialization strategies for the PharmaJet organization replacing Melissa Malhame who transitioned to a strategic advisory role for the company. DetailsThe Lancet Publication Confirms Viability of Intradermal Polio Vaccination
GOLDEN, Colo. — June 3, 2021- A systematic review and meta-analysis published in the April 30, 2021 issue of The Lancet strengthens evidence from previous publications that fractional dose delivery is a viable alternative to full dose inactivated polio vaccine (IPV). Previous studies have shown that two doses of intradermally-delivered IPV (60% less vaccine) were more immunogenic than one full dose delivered intramuscularly. Intradermal fractional dose delivery also lowers the total cost of vaccination substantially. DetailsPharmaJet presents Needle-free delivery of Covid-19 DNA vaccine results at World Vaccine Congress
GOLDEN, Colo. — April 27, 2021 — PharmaJet®, the maker of innovative, needle-free injection technology, announced that their latest research results will be presented at the World Vaccine Congress on May 6. The presentation, entitled Progress of COVID-19 Vaccines with Needle-Free Delivery, is being presented by Erin K. Spiegel, PhD, Vice President, Clinical & Regulatory Affairs at PharmaJet, Inc. DetailsGlobal NGO expands use of PharmaJet for Polio Eradication Campaigns
GOLDEN, Colo. — March 9, 2021 — PharmaJet ® , the maker of innovative, needle-free injection technology, today announced that a global NGO (Non-governmental organization) has expanded the use of its Tropis® Needle-free Injection System in polio eradication campaigns. The latest country addition, Somalia, adds to the already successful vaccination programs in Pakistan, Cuba, The Gambia and others.
Details